Breakthrough SARS-CoV-2 infections after vaccination: a critical review

References

• Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh A, Yeganeh B, Mohseni S, Mehraeen R, Sepidarkish M, Bijani A, et al. Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study. Rom J Intern Med. 2020;58(3):161–5. doi:10.2478/rjim-2020-0013.
   PubMed Web of Science ®Google Scholar
• Javanian M, Bayani M, Shokri M, Sadeghi-Haddad-Zavareh M, Babazadeh A, Ghadimi R, Sepidarkish M, Bijani A, Yahyapour Y, Barary M, et al. Risk factors for mortality of 557 adult patients with COVID 19 in Babol, Northern Iran: a retrospective cohort study. Bratisl Lek Listy. 2021;122(1):34–38. doi:10.4149/BLL_2021_003.
   PubMed Web of Science ®Google Scholar
• Javanian M, Masrour-Roudsari J, Bayani M, Ebrahimpour S. Coronavirus disease 2019 (COVID-19): what we need to know. Caspian J Internal Med. 2020;11(2):235–36. doi:10.22088/cjim.11.2.23.
   PubMed Web of Science ®Google Scholar
• Boyton RJ, Altmann DM. Risk of SARS-CoV-2 reinfection after natural infection. Lancet. 2021;397(10280):1161–63. doi:10.1016/S0140-6736(21)00662-0.
   PubMed Web of Science ®Google Scholar
• Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, Kedia S, Sankar J, Kumar P, Kumar A, et al. SARS-CoV-2 reinfection rate and estimated effectiveness of the inactivated whole virion vaccine BBV152 against reinfection among health care workers in New Delhi, India. JAMA Netw Open. 2022;5(1):e2142210. doi:10.1001/jamanetworkopen.2021.42210.
   PubMed Web of Science ®Google Scholar
• Malhotra S, Mani K, Lodha R, Bakhshi S, Mathur VP, Gupta P, Kedia S, Sankar J, Kumar P, Kumar A, et al. Anti-SARS-CoV-2 antibodies persist for up to 13 months and reduce risk of reinfection. medRxiv; 2021.
   Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD, et al. Bnt162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23. doi:10.1056/NEJMoa2101765.
   PubMed Web of Science ®Google Scholar
• Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman M, Garcia-Beltran WF, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52). doi:10.1126/sciimmunol.abe0367.
   PubMed Web of Science ®Google Scholar
• Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–30. doi:10.1126/science.abd7728.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529). doi:10.1126/science.abf4063.
   PubMed Web of Science ®Google Scholar
• McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–34. doi:10.1038/s41586-020-03041-6.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–63. doi:10.1126/science.abc7520.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals. Regeneronreports positive interim data with regen-CoV™ antibody cocktail used as passivevaccine to prevent COVID-19; 2021 January 26.
   Google Scholar
• Huang WC, Huang LM, Chang IS, Tsai FY, Chang LY. Varicella breakthrough infection and vaccine effectiveness in Taiwan. Vaccine. 2011;29(15):2756–60. doi:10.1016/j.vaccine.2011.01.092.
   PubMed Web of Science ®Google Scholar
• Adebanjo TA, Pondo T, Yankey D, Hill HA, Gierke R, Apostol M, Barnes M, Petit S, Farley M, Harrison LH, et al. Pneumococcal conjugate vaccine breakthrough infections: 2001–2016. Pediatrics. 2020;145(3). doi:10.1542/peds.2019-0836.
   PubMed Web of Science ®Google Scholar
• Tyagi K, Ghosh A, Nair D, Dutta K, Singh Bhandari P, Ahmed Ansari I, Misra A. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021;15(3):1007–08. doi:10.1016/j.dsx.2021.05.001.
   PubMedGoogle Scholar
• Munoz FM, Cramer JP, Dekker CL, Dudley MZ, Graham BS, Gurwith M, Law B, Perlman S, Polack FP, Spergel JM, et al. Vaccine-Associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39(22):3053–66. doi:10.1016/j.vaccine.2021.01.055.
   PubMed Web of Science ®Google Scholar
• Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020;101(8):791. doi:10.1099/jgv.0.001439.
   PubMed Web of Science ®Google Scholar
• Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–82. doi:10.1056/NEJMc2032195.
   PubMed Web of Science ®Google Scholar
• Giannitsarou C, Kissler S, Toxvaerd F. Waning immunity and the second wave: some projections for SARS-CoV-2 American Economic Review: Insights. 2021;3:8–321.
   Google Scholar
• Zilla ML, Keetch C, Mitchell G, McBreen J, Shurin MR, Wheeler SE. SARS-CoV-2 serologic immune response in exogenously immunosuppressed patients. J Appl Lab Med. 2021;6(2):486–90. doi:10.1093/jalm/jfaa232.
   PubMedGoogle Scholar
• Heeger PS, Larsen CP, Segev DL. Implications of defective immune responses in SARS-CoV-2–vaccinated organ transplant recipients. Sci Immunol. 2021;6(61). doi:10.1126/sciimmunol.abj6513.
   PubMed Web of Science ®Google Scholar
• Geisen UM, Berner DK, Tran F, Sumbul M, Vullriede L, Ciripoi M, Reid HM, Schaffarzyk A, Longardt AC, Franzenburg J, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021;80(10):1306–11. doi:10.1136/annrheumdis-2021-220272.
   PubMed Web of Science ®Google Scholar
• McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. Npj Vaccines. 2021;6(1):1–14. doi:10.1038/s41541-021-00336-1.
   PubMed Web of Science ®Google Scholar
• Keehner J, Horton LE, Pfeffer MA, Longhurst CA, Schooley RT, Currier JS, Abeles SR, Torriani FJ. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021;384(18):1774–75. doi:10.1056/NEJMc2101927.
   PubMed Web of Science ®Google Scholar
• Jacobson KB, Pinsky BA, Montez Rath ME, Wang H, Miller JA, Skhiri M, Shepard J, Mathew R, Lee G, Bohman B, et al. Post-Vaccination SARS-CoV-2 infections and incidence of presumptive B. 1.427/B. 1.429 variant among healthcare personnel at a northern California academic medical center. Clin Infect Dis. 2021. doi:10.1093/cid/ciab554.
   Web of Science ®Google Scholar
• England PH Annex A: report to JCVI on estimated efficacy of a single dose of Pfizer BioNtech (Bnt162b2 mRNA) vaccine and of a single dose of ChAdox1 vaccine (AZD1222); 2020.
   Google Scholar
• Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, Tian Y, Florea A, Aragones M, Tubert JE, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. Bmj. 2021;375:e068848. doi:10.1136/bmj-2021-068848.
   PubMed Web of Science ®Google Scholar
• Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken Dror S, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27(8) :1379–1384.
   PubMed Web of Science ®Google Scholar
• Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, Jones J, House T, VanSteenHouse H, Bell I, et al. Impact of vaccination on new SARS-CoV-2 infections in the UK. medRxiv; 2021;27.
   Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184(9):2348–61 e6. doi:10.1016/j.cell.2021.02.037.
   PubMed Web of Science ®Google Scholar
• Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, et al. Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. 2021;384(23):2212–18. doi:10.1056/NEJMoa2105000.
   PubMed Web of Science ®Google Scholar
• Conti P, Caraffa A, Gallenga C, Kritas S, Frydas I, Younes A, Di Emidio P, Tetè G, Pregliasco F, Ronconi G, et al. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem. J Biol Regul Homeost Agents. 2021;35(1):1–4.
   PubMed Web of Science ®Google Scholar
• McEwen AE, Cohen S, Bryson-Cahn C, Liu C, Pergam SA, Lynch J, Schippers A, Strand K, Whimbey E, Mani NS, et al. Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. medRxiv; 2021.
   Google Scholar
• Bouton TC, Lodi S, Turcinovic J, Weber SE, Quinn E, Korn C, Steiner J, Schechter-Perkins EM, Duffy E, et al. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination strain sequences among healthcare workers at an urban academic medical center: a prospective cohort study. medRxiv; 2021.
   Google Scholar
• Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021;397(10286):1725–35. doi:10.1016/S0140-6736(21)00790-X.
   PubMed Web of Science ®Google Scholar
• Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, et al. Decreased SARS-CoV-2 viral load following vaccination. MedRxiv; 2021.
   Google Scholar
• Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, Ben-Ami R. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. Jama. 2021;325(24):2457. doi:10.1001/jama.2021.7152.
   PubMed Web of Science ®Google Scholar
• Bleier BS, Ramanathan M Jr, Lane AP. COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission. Otolaryngol Head Neck Surg. 2021;164(2):305–07. doi:10.1177/0194599820982633.
   PubMed Web of Science ®Google Scholar
• Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790–92. doi:10.1038/s41591-021-01316-7.
   PubMed Web of Science ®Google Scholar
• Mor V, Gutman R, Yang X, White EM, McConeghy KW, Feifer RA, Blackman CR, Kosar CM, Bardenheier BH, Gravenstein SA, et al. Short-Term impact of nursing home SARS-CoV -2 vaccinations on new infections, hospitalizations, and deaths. J Am Geriatr Soc. 2021;69(8):2063–69. doi:10.1111/jgs.17176.
   PubMed Web of Science ®Google Scholar
• Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, Canas LS, Graham MS, Klaser, K, Modat M, et al. Post-Vaccination SARS-CoV-2 infection: risk factors and illness profile in a prospective, observational community-based case-control study. medRxiv; 2021.
   Google Scholar
• Alene M, Yismaw L, Assemie MA, Ketema DB, Gietaneh W, Birhan TY. Serial interval and incubation period of COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):1–9. doi:10.1186/s12879-021-05950-x.
   PubMed Web of Science ®Google Scholar
• Qin J, You C, Lin Q, Hu T, Yu S, Zhou X-H. Estimation of incubation period distribution of COVID-19 using disease onset forward time: a novel cross-sectional and forward follow-up study. Sci Adv. 2020;6(33):eabc1202. doi:10.1126/sciadv.abc1202.
   PubMed Web of Science ®Google Scholar
• Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. Jama. 2021;325(13):1318–20. doi:10.1001/jama.2021.3199.
   PubMed Web of Science ®Google Scholar
• Jęśkowiak I, Wiatrak Bg, Grosman-Dziewiszek P, Szeląg A. The incidence and severity of post-vaccination reactions after vaccination against COVID-19. Vaccines. 2021;9(5):502. doi:10.3390/vaccines9050502.
   Web of Science ®Google Scholar
• Al-Maqbali JS, Al Rasbi S, Kashoub MS, Al Hinaai AM, Farhan H, Al Rawahi B, Al Alawi AM. A 59-Year-old woman with extensive deep vein thrombosis and pulmonary thromboembolism 7 days following a first dose of the Pfizer-BioNtech BNT162b2 mRNA COVID-19 vaccine. Am J Case Rep. 2021;22. doi:10.12659/AJCR.932946.
   Web of Science ®Google Scholar